Merck, Pfizer won their FDA nod for fourth-to-market SGLT2 drug Steglatro. Now what?
admin 21st December 2017 Uncategorised 0One of the fastest-growing classes of diabetes drugs now has a new contender: Steglatro, the SGLT2 drug from Merck & Co. and Pfizer. When it rolls out in January, the drug will have to tackle the tough task of winning share from some already entrenched rivals.
More: Merck, Pfizer won their FDA nod for fourth-to-market SGLT2 drug Steglatro. Now what?
Source: fierce